We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05643508
Recruitment Status : Not yet recruiting
First Posted : December 8, 2022
Last Update Posted : December 12, 2022
Sponsor:
Information provided by (Responsible Party):
Daewoong Pharmaceutical Co. LTD.

Brief Summary:
This study aims to evaluate the efficacy and safety of co-administration of DWC202206 and DWC202207 in patients with concomitant hypertension and hyperlipidemia.

Condition or disease Intervention/treatment Phase
Hypertension Hyperlipidemias Drug: (D) DWC202206 Drug: (D) DWC202207 Drug: (P) DWC202206 Drug: (P) DWC202207 Phase 3

Detailed Description:
The study design is a randomized, double-blind, multicenter clinical trial. The patients were randomly assigned to each group. Primary endpoint was the change of MSSBP based on baseline between Treatment arm and control 1 arm and the change of LDL-C based on baseline between arm and control 2 arm.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 192 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Multicenter Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Hypertension and Dyslipidemia
Estimated Study Start Date : December 2022
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : March 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: (D) DWC202206 + DWC202207 Drug: (D) DWC202206
Drug of DWC202206 A mg

Drug: (D) DWC202207
Drug of DWC202207 B/C mg

Active Comparator: (P+D) DWC202206 + DWC202207 Drug: (D) DWC202207
Drug of DWC202207 B/C mg

Drug: (P) DWC202206
Placebo of DWC202206 A mg

Active Comparator: (D+P) DWC202206 + DWC202207 Drug: (D) DWC202206
Drug of DWC202206 A mg

Drug: (P) DWC202207
Placebo of DWC202207 B/C mg




Primary Outcome Measures :
  1. The change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baseline between treatment arm and control 1 arm [ Time Frame: 8 weeks ]
  2. The change of LDL-C based on baseline between treatment arm and control 2 arm [ Time Frame: 8 weeks ]

Secondary Outcome Measures :
  1. The change of MSSBP (Mean Sitting Systolic Blood Pressure) based on baseline between treatment arm and control 1 arm [ Time Frame: 4 weeks ]
  2. The change of LDL-C based on baseline between treatment arm and control 2 arm [ Time Frame: 4 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 19 to 80 years
  • Patients with hypertension and hyperlipidemias

Exclusion Criteria:

  • Orthostatic hypotension
  • History of ventricular tachycardia, atrial fibrillation
  • Uncontrolled diabetes mellitus
Layout table for additonal information
Responsible Party: Daewoong Pharmaceutical Co. LTD.
ClinicalTrials.gov Identifier: NCT05643508    
Other Study ID Numbers: DW_DWJ1575301
First Posted: December 8, 2022    Key Record Dates
Last Update Posted: December 12, 2022
Last Verified: December 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Hyperlipidemias
Hyperlipoproteinemias
Vascular Diseases
Cardiovascular Diseases
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases